Literature DB >> 24567255

Effects of Kaixin Jieyu Decoction () on behavior, monoamine neurotransmitter levels, and serotonin receptor subtype expression in the brain of a rat depression model.

Shi-jing Huang1, Xian-hui Zhang2, Yan-yun Wang2, Ju-hua Pan2, Han-ming Cui2, Su-ping Fang2, Wei Wu2, Jun Zheng2, Duo-jiao Li2, Ge Bai2.   

Abstract

OBJECTIVE: To determine the mechanisms underlying the anti-depressant effects of Kaixin Jieyu Decoction (, KJD) by investigating the effects of KJD on behavior, monoamine neurotransmitter levels, and serotonin (5-HT) receptor subtype expression in the brain in a rat model of depression.
METHODS: The rat depression model was established using chronic unpredictable mild stress (CUMS). Forty-eight Sprague Dawley rats were randomly divided into control, depression model (CUMS), CUMS+KJD (7.7 g/kg(-1)·d(-1) of crude drug), and CUMS+fluoxetine (2.4 mg/kg(-1)·d(-1)) groups (n=12 in each group), and the treatments lasted for 21 days. We regularly evaluated body weight, sucrose consumption, and horizontal and vertical activity scores in open-field tests. The content of the monoamine neurotransmitters 5-HT, norepinephrine (NE), and dopamine (DA) and the DA metabolite homovanillic acid in the cerebral cortex, and 5-HT1A and 5-HT2A receptor mRNA in the cerebral cortex and the hippocampus, were determined respectively by high-performance liquid chromatography-coularray electrochemical detector and real-time polymerase chain reaction.
RESULTS: Compared with the control group, CUMS rats showed a variety of depression-like behavioral changes, including a significant reduction in body weight, sucrose consumption, and horizontal and vertical activity scores in open-field tests (P<0.05 or P<0.01), and a significant decrease in 5-HT and NE levels and 5-HT2A receptor mRNA expression. In contrast, they showed a significant increase in 5-HT1A receptor mRNA expression in the cerebral cortex. In the hippocampus, 5-HT1A receptor mRNA expression was lower whereas 5-HT2A receptor mRNA expression was higher than in the control group (P<0.05 or P<0.01). Treatment with KJD or fluoxetine partially attenuated these changes (P<0.05 or P<0.01).
CONCLUSION: KJD could normalize the levels of 5-HT and NE and adjust the balance of 5-HT1A and 5-HT2A receptor expression in rat cerebrum, and this may be one of mechanisms of antidepressant effects of KJD.

Entities:  

Keywords:  Kaixin Jieyu Decoction; behavior; depression; monoamines neurotransmitter; serotonin1A and serotonin2A receptor mRNA

Mesh:

Substances:

Year:  2014        PMID: 24567255     DOI: 10.1007/s11655-014-1343-0

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  19 in total

1.  Effect of chronic unpredictable mild stress on brain-pancreas relative protein in rat brain and pancreas.

Authors:  Yan-Hua Lin; Ai-Hua Liu; Ying Xu; Lu Tie; He-Ming Yu; Xue-Jun Li
Journal:  Behav Brain Res       Date:  2005-09-08       Impact factor: 3.332

2.  The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.

Authors:  Gerard J Marek; Raul Martin-Ruiz; Allyson Abo; Francesc Artigas
Journal:  Neuropsychopharmacology       Date:  2005-12       Impact factor: 7.853

3.  Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats.

Authors:  Mirjana Carli; Marta Baviera; Roberto W Invernizzi; Claudia Balducci
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

Review 4.  New approaches to antidepressant drug discovery: beyond monoamines.

Authors:  Olivier Berton; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2006-02       Impact factor: 34.870

5.  Early life blockade of 5-hydroxytryptamine 1A receptors normalizes sleep and depression-like behavior in adult knock-out mice lacking the serotonin transporter.

Authors:  Chloé Alexandre; Daniela Popa; Véronique Fabre; Saoussen Bouali; Patrice Venault; Klaus-Peter Lesch; Michel Hamon; Joëlle Adrien
Journal:  J Neurosci       Date:  2006-05-17       Impact factor: 6.167

6.  Neuropharmacology of 5-hydroxytryptamine.

Authors:  A Richard Green
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 7.  New drug targets in the signaling pathways activated by antidepressants.

Authors:  Marcelo Páez-Pereda
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-07       Impact factor: 5.067

Review 8.  Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system.

Authors:  Małgorzata Filip; Michael Bader
Journal:  Pharmacol Rep       Date:  2009 Sep-Oct       Impact factor: 3.024

9.  Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons.

Authors:  Steven T Szabo; Pierre Blier
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.

Authors:  Martin M Katz; Janet L Tekell; Charles L Bowden; Steve Brannan; John P Houston; Nancy Berman; Alan Frazer
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

View more
  3 in total

1.  Effects of kaixin jieyu decoction on behavior and glial fibrillary acidic protein expression in cerebral hippocampus of a rat vascular depression model.

Authors:  Xian-hui Zhang; Shi-jing Huang; Yan-yun Wang; Ying Zhang; Ju-hua Pan; Jun Zheng; Duo-jiao Li; Xiao-ming Lei
Journal:  Chin J Integr Med       Date:  2014-08-06       Impact factor: 1.978

2.  Protective effects of silibinin and its possible mechanism of action in mice exposed to chronic unpredictable mild stress.

Authors:  Wen-Jing Yan; Ying-Chun Tan; Ji-Cheng Xu; Xian-Ping Tang; Chong Zhang; Peng-Bo Zhang; Ze-Qiang Ren
Journal:  Biomol Ther (Seoul)       Date:  2015-05-01       Impact factor: 4.634

3.  Effects of Kaixinjieyu, a Chinese herbal medicine preparation, on neurovascular unit dysfunction in rats with vascular depression.

Authors:  Juhua Pan; Xiaoming Lei; Jialong Wang; Shijing Huang; Yanyun Wang; Ying Zhang; Wen Chen; Duojiao Li; Jun Zheng; Hanming Cui; Qihua Liu
Journal:  BMC Complement Altern Med       Date:  2015-08-19       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.